miR-375 inhibits the proliferation of gastric cancer cells by repressing ERBB2 expression

被引:47
|
作者
Shen, Zhi-Yong [1 ]
Zhang, Zi-Zhen [1 ]
Liu, Hua [1 ]
Zhao, En-Ha [1 ]
Cao, Hui [1 ]
机构
[1] Shanghai Jiao Tong Univ, Dept Gen Surg, Renji Hosp, Sch Med, Shanghai 201112, Peoples R China
基金
中国国家自然科学基金;
关键词
gastric cancer; microRNA; human epidermal growth factor receptor 2; proliferation; MICRORNA EXPRESSION; SCORING SYSTEM; HER2; DYSREGULATION; CARCINOMA; SURVIVAL;
D O I
10.3892/etm.2014.1627
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate the expression of targeted genes in a post-transcriptional manner. Increasing evidence indicates that miRNAs play important roles in cancer pathogenesis, including apoptosis, proliferation and differentiation, as oncogenes or tumor suppressors. Previously, miR-375 was shown to be involved in human gastric cancer, however, the mechanism remains poorly understood. In the present study, miR-375 was shown to be downregulated in gastric cancer tissues, particularly human epidermal growth factor receptor 2 (ERBB2)-positive gastric cancer tissues. Identified by dual luciferase assays and western blot analysis, ERBB2 was demonstrated to be a target gene of miR-375. In addition, miR-375 overexpression suppressed the proliferation of human gastric cancer cells in vitro and the suppression effect was restored by ERBB2 overexpresion. Thus, the results of the present study indicate that miR-375 is associated with human gastric carcinogenesis by targeting ERBB2. Therefore, miR-375 may be used as a potential clinical classification marker and therapeutic target for human gastric cancer.
引用
收藏
页码:1757 / 1761
页数:5
相关论文
共 50 条
  • [31] Aspirin inhibits ErbB2 to induce apoptosis in cervical cancer cells
    Xiang, Shuanglin
    Sun, Zhenhua
    He, Qiongzhi
    Yan, Feng
    Wang, Yijun
    Zhang, Jian
    MEDICAL ONCOLOGY, 2010, 27 (02) : 379 - 387
  • [32] miR-1296-5p decreases ERBB2 expression to inhibit the cell proliferation in ERBB2-positive breast cancer
    Chen, Gang
    He, Mingfeng
    Yin, Yin
    Yan, Ting
    Cheng, Wenfang
    Huang, Zebo
    Zhang, Lan
    Zhang, Huo
    Liu, Ping
    Zhu, Wei
    Zhu, Yichao
    CANCER CELL INTERNATIONAL, 2017, 17
  • [33] Gastric cancer: Differential expression of genes inside the ERBB2 amplicon
    Zaika, A
    Varis, A
    Knuutila, S
    Moskaluk, C
    El-Rifai, W
    GASTROENTEROLOGY, 2004, 126 (04) : A410 - A410
  • [34] Aspirin inhibits ErbB2 to induce apoptosis in cervical cancer cells
    Shuanglin Xiang
    Zhenhua Sun
    Qiongzhi He
    Feng Yan
    Yijun Wang
    Jian Zhang
    Medical Oncology, 2010, 27 : 379 - 387
  • [35] Septin oligomerization regulates persistent expression of ErbB2/HER2 in gastric cancer cells
    Marcus, Elizabeth A.
    Tokhtaeva, Elmira
    Turdikulova, Shahlo
    Capri, Joseph
    Whitelegge, Julian P.
    Scott, David R.
    Sachs, George
    Berditchevski, Fedor
    Vagin, Olga
    BIOCHEMICAL JOURNAL, 2016, 473 : 1703 - 1718
  • [36] Over-expression of microRNA-375 inhibits papillary thyroid carcinoma cell proliferation and induces cell apoptosis by targeting ERBB2
    Wang, Xin-Zheng
    Hang, Ya-Kai
    Liu, Jin-Biao
    Hou, Yong-Qiang
    Wang, Ning
    Wang, Ming-Jun
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2016, 130 (02) : 78 - 84
  • [37] ErbB2: a therapeutic target in gastric cancer
    Belle, S.
    Ebert, M. P.
    GASTROENTEROLOGE, 2012, 7 (01): : 8 - 13
  • [38] RETRACTION: Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2
    Zhou, Ning
    Qu, Yanli
    Xu, Chunlei
    Tang, Yong
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2025, 29 (03)
  • [39] Inhibition of migration and invasion of gastric cancer cells by Snail-regulated MiR-375 through JAK2 targeting
    Xu Yanjun
    Zhou Tianhua
    Si Jianmin
    Zhuo Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [40] Expression of ERBB2 and PD1 mRNA in advanced gastric cancer
    Pesantez, D.
    Braso-Maristany, F.
    Esposito, F.
    Oberoi, H. K.
    Oliveres, H.
    Pascual, T.
    Cuatrecasas, M.
    Teixido Febrero, C.
    Sanfeliu, E.
    Laguna, J. C.
    Segui, E.
    Perez, A.
    Martinez, D.
    Guerrero, J.
    Lopez, S.
    Fernandez-Esparrach, G.
    Momblan, D.
    Fillat, C.
    Prat, A.
    Sauri, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S922 - S923